JP Morgan initiated coverage on Enovis Corporation with a new price target
$ENOV
Industrial Specialties
Health Care
JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/3/2024 | $62.00 | Mkt Outperform | JMP Securities |
| 6/13/2024 | $53.00 | Neutral | JP Morgan |
| 2/13/2024 | $72.00 | Overweight | Stephens |
| 1/22/2024 | $75.00 | Buy | UBS |
| 1/3/2024 | Outperform | William Blair | |
| 12/15/2023 | $62.00 → $70.00 | Buy | Needham |
| 10/20/2023 | $75.00 | Buy | ROTH MKM |
| 6/26/2023 | $70.00 | Buy | Needham |
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00
JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00
Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00
Wilmington, DE, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Jefferies London Healthcare Conference: Matt Trerotola, Chair and Chief Executive Officer, and Ben Berry, Chief Financial Officer, will participate in a fireside chat on Wednesday, November 20th at 12:00 p.m. GMT (7:00 a.m. ET)Evercore 7th Annual HealthCONx Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Wednesday, December 4th at 10:50 a.m. ET. A link to the live audio webcasts, as well as a replay of these events,
Continued commercial momentum with third-quarter sales growth of 21% on a reported basis and strong adjusted EBITDA margin expansionReconstructive sales grew 57% Y/Y on a reported basis and 9% on a Comparable basisReported third-quarter net loss from continuing operations of $0.61 per share, adjusted net income per diluted share of $0.73, up +30% Y/Y Wilmington, DE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended September 27, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:3
Wilmington, DE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2024 financial results on Wednesday, November 6th, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715
In the latest quarter, 4 analysts provided ratings for Enovis (NYSE:ENOV), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 1 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $69.75, a high estimate of $82.00, and a low estimate of $53.00. This current average represents a 8.22% decr
Evercore ISI Group analyst Vijay Kumar maintains Enovis (NYSE:ENOV) with a Outperform and lowers the price target from $70 to $62.
Continued commercial momentum with third-quarter sales growth of 21% on a reported basis and strong adjusted EBITDA margin expansionReconstructive sales grew 57% Y/Y on a reported basis and 9% on a Comparable basisReported third-quarter net loss from continuing operations of $0.61 per share, adjusted net income per diluted share of $0.73, up +30% Y/Y Wilmington, DE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended September 27, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:3
Wilmington, DE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2024 financial results on Wednesday, November 6th, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715
Continued strong momentum with second-quarter sales growth of 23% on a reported basis and strong adjusted margin expansionReported second-quarter net loss from continuing operations of $0.34 per share with adjusted net income per diluted share of $0.62Advanced strategic goals with solid first half of 2024, slightly ahead of expectations, and set up to accelerate in the second half of the year Wilmington, DE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 28, 2024. The Company will host an investor conference call and live webcast to discuss
SCHEDULE 13G - Enovis CORP (0001420800) (Subject)
10-Q - Enovis CORP (0001420800) (Filer)
8-K - Enovis CORP (0001420800) (Filer)
SC 13G/A - Enovis CORP (0001420800) (Subject)
SC 13G/A - Enovis CORP (0001420800) (Subject)
SC 13G/A - Enovis CORP (0001420800) (Subject)
WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
Massimo Calafiore begins as President and Chief Executive Officer, effective immediately Julie Andrews is appointed as Chief Financial Officer, assuming the role effective January 15, 2024 Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that effective immediately, Massimo Calafiore has assumed the role of President and Chief Executive Officer (CEO) and as a member of the Orthofix Board of Directors. In conjunction with Mr. Calafiore stepping into his role as CEO, the Company has announced the appointment of Julie Andrews as Chief Financial Officer. Ms. Andrews previously served as CFO for Smart Wires Technology, where she led all f